S. Kadono

发表

Ligand-induced changes in the conformation of 3-isopropylmalate dehydrogenase from Thermus thermophilus.

T. Oshima, N. Tanaka, H. Moriyama, 1995, Journal of biochemistry.

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant

S. Kadono, T. Igawa, F. Mimoto, 2013, mAbs.

Design and synthesis of peptidomimetic factor VIIa inhibitors.

S. Kadono, T. Shiraishi, Yoshiaki Watanabe, 2010, Chemical & pharmaceutical bulletin.

Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.

S. Kadono, T. Shiraishi, Yoshiaki Watanabe, 2008, Bioorganic & medicinal chemistry letters.

Crystal structure of human factor VIIa/tissue factor in complex with peptide mimetic inhibitor.

S. Kadono, T. Shiraishi, Yoshiaki Watanabe, 2004, Biochemical and biophysical research communications.

Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor.

Tsukasa Suzuki, S. Kadono, T. Shiraishi, 2005, Biochemical and Biophysical Research Communications - BBRC.

Novel interactions of large P3 moiety and small P4 moiety in the binding of the peptide mimetic factor VIIa inhibitor.

Tsukasa Suzuki, S. Kadono, T. Shiraishi, 2005, Biochemical and biophysical research communications.

Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment.

M. Ishii, S. Kadono, Y. Azuma, 2020, Cell reports.

Structure of human factor VIIa/tissue factor in complex with a peptide-mimetic inhibitor: high selectivity against thrombin by introducing two charged groups in P2 and P4.

S. Kadono, T. Shiraishi, Yoshiaki Watanabe, 2005, Acta crystallographica. Section F, Structural biology and crystallization communications.

Structure-Based Drug Design of Peptide Mimetics Containing Large P3 Moieties as Inhibitors of Factor VIIa

S. Kadono, T. Shiraishi, Yoshiaki Watanabe, 2009 .

Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation.

K. Jishage, O. Ueda, S. Kadono, 2020, Cancer discovery.

Novel potent and highly selective DDR1 inhibitors from integrated lead finding

B. Kuhn, M. Rudolph, M. Prunotto, 2023, Medicinal Chemistry Research.

The crystal structure of thermostable mutants of chimeric 3-isopropylmalate dehydrogenase, 2T2M6T.

T. Oshima, A. Yamagishi, N. Tanaka, 1995, Protein Engineering.